In my view, the market appears focused on Agios Pharmaceuticals, Inc.'s ( AGIO ) continued net losses, as well as the discontinuation of tebapivat development and competition from Novo Nordisk's etavopivat; however, I think this ignores the operational leverageI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix o ...